Cargando…
Endogenous thrombin potential following hemostatic therapy with 4-factor prothrombin complex concentrate: a 7-day observational study of trauma patients
INTRODUCTION: Purified prothrombin complex concentrate (PCC) is increasingly used as hemostatic therapy for trauma-induced coagulopathy (TIC). However, the impact of PCC administration on coagulation status among patients with TIC has not been adequately investigated. METHODS: In this observational,...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4227066/ https://www.ncbi.nlm.nih.gov/pubmed/25008277 http://dx.doi.org/10.1186/cc13982 |
_version_ | 1782343727984934912 |
---|---|
author | Schöchl, Herbert Voelckel, Wolfgang Maegele, Marc Kirchmair, Lukas Schlimp, Christoph J |
author_facet | Schöchl, Herbert Voelckel, Wolfgang Maegele, Marc Kirchmair, Lukas Schlimp, Christoph J |
author_sort | Schöchl, Herbert |
collection | PubMed |
description | INTRODUCTION: Purified prothrombin complex concentrate (PCC) is increasingly used as hemostatic therapy for trauma-induced coagulopathy (TIC). However, the impact of PCC administration on coagulation status among patients with TIC has not been adequately investigated. METHODS: In this observational, descriptive study, data relating to thrombin generation were obtained from plasma samples gathered prospectively from trauma patients upon emergency room (ER) admission and over the following 7 days. Standard coagulation tests, including measurement of antithrombin (AT) and fibrinogen, were performed. Three groups were investigated: patients receiving no coagulation therapy (NCT group), patients receiving fibrinogen concentrate only (FC group), and patients treated with PCC and fibrinogen concentrate (FC-PCC group). RESULTS: The study population (77 patients) was predominantly male (84.4%); mean age was 40 ± 15 years and mean injury severity score was 25.6 ± 12.7. There were no significant differences between the three study groups in thrombin-related parameters upon ER admission. Endogenous thrombin potential (ETP) was significantly higher in the FC-PCC group compared with the NCT group on days 1 to 4 and the FC group on days 1 to 3. AT levels were significantly lower in the FC-PCC group from admission until day 3 (versus FC group) or day 4 (versus NCT group). Fibrinogen increased over time, with no significant between-group differences after ER admission. Despite ETP being higher, prothrombin time and activated partial thromboplastin time were significantly prolonged in the FC-PCC group from admission until day 3 to 4. CONCLUSIONS: Treatment with PCC increased ETP for several days, and patients receiving PCC therapy had low AT concentrations. These findings imply a potential pro-thrombotic state not reflected by standard coagulation tests. This is probably important given the postoperative acute phase increase in fibrinogen levels, although studies with clinical endpoints are needed to ascertain the implications for patient outcomes. We recommend careful use of PCC among trauma patients, with monitoring and potentially supplementation of AT. |
format | Online Article Text |
id | pubmed-4227066 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-42270662014-11-12 Endogenous thrombin potential following hemostatic therapy with 4-factor prothrombin complex concentrate: a 7-day observational study of trauma patients Schöchl, Herbert Voelckel, Wolfgang Maegele, Marc Kirchmair, Lukas Schlimp, Christoph J Crit Care Research INTRODUCTION: Purified prothrombin complex concentrate (PCC) is increasingly used as hemostatic therapy for trauma-induced coagulopathy (TIC). However, the impact of PCC administration on coagulation status among patients with TIC has not been adequately investigated. METHODS: In this observational, descriptive study, data relating to thrombin generation were obtained from plasma samples gathered prospectively from trauma patients upon emergency room (ER) admission and over the following 7 days. Standard coagulation tests, including measurement of antithrombin (AT) and fibrinogen, were performed. Three groups were investigated: patients receiving no coagulation therapy (NCT group), patients receiving fibrinogen concentrate only (FC group), and patients treated with PCC and fibrinogen concentrate (FC-PCC group). RESULTS: The study population (77 patients) was predominantly male (84.4%); mean age was 40 ± 15 years and mean injury severity score was 25.6 ± 12.7. There were no significant differences between the three study groups in thrombin-related parameters upon ER admission. Endogenous thrombin potential (ETP) was significantly higher in the FC-PCC group compared with the NCT group on days 1 to 4 and the FC group on days 1 to 3. AT levels were significantly lower in the FC-PCC group from admission until day 3 (versus FC group) or day 4 (versus NCT group). Fibrinogen increased over time, with no significant between-group differences after ER admission. Despite ETP being higher, prothrombin time and activated partial thromboplastin time were significantly prolonged in the FC-PCC group from admission until day 3 to 4. CONCLUSIONS: Treatment with PCC increased ETP for several days, and patients receiving PCC therapy had low AT concentrations. These findings imply a potential pro-thrombotic state not reflected by standard coagulation tests. This is probably important given the postoperative acute phase increase in fibrinogen levels, although studies with clinical endpoints are needed to ascertain the implications for patient outcomes. We recommend careful use of PCC among trauma patients, with monitoring and potentially supplementation of AT. BioMed Central 2014 2014-07-09 /pmc/articles/PMC4227066/ /pubmed/25008277 http://dx.doi.org/10.1186/cc13982 Text en Copyright © 2014 Schöchl et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Schöchl, Herbert Voelckel, Wolfgang Maegele, Marc Kirchmair, Lukas Schlimp, Christoph J Endogenous thrombin potential following hemostatic therapy with 4-factor prothrombin complex concentrate: a 7-day observational study of trauma patients |
title | Endogenous thrombin potential following hemostatic therapy with 4-factor prothrombin complex concentrate: a 7-day observational study of trauma patients |
title_full | Endogenous thrombin potential following hemostatic therapy with 4-factor prothrombin complex concentrate: a 7-day observational study of trauma patients |
title_fullStr | Endogenous thrombin potential following hemostatic therapy with 4-factor prothrombin complex concentrate: a 7-day observational study of trauma patients |
title_full_unstemmed | Endogenous thrombin potential following hemostatic therapy with 4-factor prothrombin complex concentrate: a 7-day observational study of trauma patients |
title_short | Endogenous thrombin potential following hemostatic therapy with 4-factor prothrombin complex concentrate: a 7-day observational study of trauma patients |
title_sort | endogenous thrombin potential following hemostatic therapy with 4-factor prothrombin complex concentrate: a 7-day observational study of trauma patients |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4227066/ https://www.ncbi.nlm.nih.gov/pubmed/25008277 http://dx.doi.org/10.1186/cc13982 |
work_keys_str_mv | AT schochlherbert endogenousthrombinpotentialfollowinghemostatictherapywith4factorprothrombincomplexconcentratea7dayobservationalstudyoftraumapatients AT voelckelwolfgang endogenousthrombinpotentialfollowinghemostatictherapywith4factorprothrombincomplexconcentratea7dayobservationalstudyoftraumapatients AT maegelemarc endogenousthrombinpotentialfollowinghemostatictherapywith4factorprothrombincomplexconcentratea7dayobservationalstudyoftraumapatients AT kirchmairlukas endogenousthrombinpotentialfollowinghemostatictherapywith4factorprothrombincomplexconcentratea7dayobservationalstudyoftraumapatients AT schlimpchristophj endogenousthrombinpotentialfollowinghemostatictherapywith4factorprothrombincomplexconcentratea7dayobservationalstudyoftraumapatients |